bisoprolol has been researched along with Disease Exacerbation in 16 studies
Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In experimental PH, treatment with bisoprolol delays progression toward right heart failure, and partially preserves RV systolic and diastolic function." | 7.78 | Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension. ( Bogaards, SJ; de Man, FS; Handoko, ML; Paulus, WJ; Postmus, PE; Schalij, I; van Ballegoij, JJ; van der Velden, J; Vonk-Noordegraaf, A; Westerhof, N, 2012) |
| "The historical choice of angiotensin-converting enzyme (ACE) inhibition as first-line therapy in heart failure is challenged by early activation of the sympathetic system and multiple ways beta blockade (in particular, unselective agents such as carvedilol) may affect cardiac remodeling, its underlying mechanisms, and, hence, progression of heart failure, compared with ACE inhibition." | 4.84 | Beta blockers or angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker: what should be first? ( Remme, WJ, 2007) |
| "The transdermal formulation of bisoprolol may be useful for the early introduction of β-blockers in patients admitted with cardiac symptoms associated with myocardial ischemia or heart failure." | 4.02 | An attempt at administering a transdermal formulation of bisoprolol in patients with acute cardiac symptoms. ( Horiuchi, N; Kobayashi, T; Kobayashi, Y; Nakamura, S; Nakanishi, H; Naruhashi, K; Nozaki, A; Okugawa, H, 2021) |
| "In experimental PH, treatment with bisoprolol delays progression toward right heart failure, and partially preserves RV systolic and diastolic function." | 3.78 | Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension. ( Bogaards, SJ; de Man, FS; Handoko, ML; Paulus, WJ; Postmus, PE; Schalij, I; van Ballegoij, JJ; van der Velden, J; Vonk-Noordegraaf, A; Westerhof, N, 2012) |
| "Chronic obstructive pulmonary disease (COPD) is associated with significant morbidity, mortality and healthcare costs." | 3.11 | Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). ( Abbas, H; Briggs, A; Campbell, K; Chaudhuri, R; Choudhury, G; Cotton, S; Dawson, D; De Soyza, A; Devereux, G; Fielding, S; Gompertz, S; Haughney, J; Lang, CC; Lee, AJ; Lipworth, BJ; MacLennan, G; MacNee, W; McCormack, K; McMeekin, N; Mills, NL; Morice, A; Norrie, J; Petrie, MC; Price, D; Short, P; Vestbo, J; Walker, P; Wedzicha, J; Wilson, A, 2022) |
| "Heart disease in chronic obstructive pulmonary disease (COPD) is a common but neglected comorbidity." | 3.01 | Preventing adverse cardiac events (PACE) in chronic obstructive pulmonary disease (COPD): study protocol for a double-blind, placebo controlled, randomised controlled trial of bisoprolol in COPD. ( Aggarwal, A; Balicki, G; Beasley, R; Chang, CL; Cochrane, B; Di Tanna, GL; Dobler, CC; Farah, CS; Galgey, S; Hancox, RJ; Hillis, GS; Jenkins, C; Martin, A; McDonald, V; Scowcroft, CP; Wrobel, J; Yang, IA, 2021) |
| "β-blockers are an important treatment of heart failure (HF) and are useful in reducing the progression of the syndrome." | 2.48 | β-blockers in stage B: a precursor of heart failure. ( Francis, GS; Sarraf, M, 2012) |
| " To date, controlled clinical trials performed in more than 13,000 patients with chronic heart failure have consistently shown that the long term administration of beta-blockers is associated with significant improvement in left ventricular function, clinical symptoms, and survival." | 2.41 | [Role of beta-blockers in the treatment of chronic heart heart failure]. ( Czuriga, I; Edes, I, 2001) |
| "Within the COPD GOLD II stage group, there appears to be no statistically significant difference in the number of exacerbations between the patients taking verapamil and digoxin (n = 24) and the patients taking BBs alone (n = 15), although, in patients taking BBs alone, there appears to be a trend towards a decrease in the exacerbations compared to the number of exacerbations in patients taking verapamil and digoxin (p = 0." | 1.51 | Beta-blocker Use in Moderate and Severe Chronic Obstructive Pulmonary Disease. ( Bedak, O; Begic, E; Bradaric, H; Custovic, F; Durak-Nalbantic, A; Hodzic, E; Mujakovic, A; Prnjavorac, B; Zvizdic, F, 2019) |
| "Bisoprolol was found to reduce mortality and CHF exacerbation compared to carvedilol and metoprolol." | 1.46 | The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study. ( Chen, CY; Huang, YB; Kuo, CC; Liao, KM; Lin, TY, 2017) |
| "Chronic obstructive pulmonary disease (COPD) is present in approximately one-third of all congestive heart failure (CHF) patients, and is a key cause of underprescription and underdosing of β-blockers, largely owing to concerns about precipitating respiratory deterioration." | 1.42 | Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. ( Asai, K; Furuse, E; Kubota, Y; Murai, K; Nakamura, S; Shimizu, W; Tsukada, YT, 2015) |
| "Treatment with bisoprolol slowed the heart rate, and treatment with losartan lowered mean arterial pressure, confirming adequate dosing, but none of the treatments improved RV function or arrested the progression of RV hypertrophy and failure compared with vehicle." | 1.40 | Effects of bisoprolol and losartan treatment in the hypertrophic and failing right heart. ( Andersen, A; Andersen, S; Bogaard, HJ; de Man, FS; Holmboe, S; Nielsen, JM; Nielsen-Kudsk, JE; Ringgaard, S; Schultz, JG; Vildbrad, MD; Vonk-Noordegraaf, A, 2014) |
| "A couple of days after increasing the dosage of betaadrenergic- and adding calcium channel blockers due to an increased heart rate in atrial fibrillation, a 77 year old female was found in cardiogenic shock." | 1.38 | [The choked heart]. ( Furrer, F; Giambarba, C, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 4 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cotton, S | 1 |
| Devereux, G | 1 |
| Abbas, H | 1 |
| Briggs, A | 1 |
| Campbell, K | 1 |
| Chaudhuri, R | 1 |
| Choudhury, G | 1 |
| Dawson, D | 1 |
| De Soyza, A | 1 |
| Fielding, S | 1 |
| Gompertz, S | 1 |
| Haughney, J | 1 |
| Lang, CC | 1 |
| Lee, AJ | 1 |
| MacLennan, G | 1 |
| MacNee, W | 1 |
| McCormack, K | 1 |
| McMeekin, N | 1 |
| Mills, NL | 1 |
| Morice, A | 1 |
| Norrie, J | 1 |
| Petrie, MC | 1 |
| Price, D | 1 |
| Short, P | 1 |
| Vestbo, J | 1 |
| Walker, P | 1 |
| Wedzicha, J | 1 |
| Wilson, A | 1 |
| Lipworth, BJ | 1 |
| Zvizdic, F | 1 |
| Begic, E | 1 |
| Mujakovic, A | 1 |
| Hodzic, E | 1 |
| Prnjavorac, B | 1 |
| Bedak, O | 1 |
| Custovic, F | 1 |
| Bradaric, H | 1 |
| Durak-Nalbantic, A | 1 |
| Nozaki, A | 1 |
| Kobayashi, T | 1 |
| Naruhashi, K | 1 |
| Okugawa, H | 1 |
| Horiuchi, N | 1 |
| Nakanishi, H | 1 |
| Kobayashi, Y | 1 |
| Nakamura, S | 2 |
| Huang, KY | 1 |
| Tseng, PT | 1 |
| Wu, YC | 1 |
| Tu, YK | 1 |
| Stubbs, B | 1 |
| Su, KP | 1 |
| Matsuoka, YJ | 1 |
| Hsu, CW | 1 |
| Lin, CH | 1 |
| Chen, YW | 1 |
| Lin, PY | 1 |
| Martin, A | 1 |
| Hancox, RJ | 1 |
| Chang, CL | 1 |
| Beasley, R | 1 |
| Wrobel, J | 1 |
| McDonald, V | 1 |
| Dobler, CC | 1 |
| Yang, IA | 1 |
| Farah, CS | 1 |
| Cochrane, B | 1 |
| Hillis, GS | 1 |
| Scowcroft, CP | 1 |
| Aggarwal, A | 1 |
| Di Tanna, GL | 1 |
| Balicki, G | 1 |
| Galgey, S | 1 |
| Jenkins, C | 1 |
| Liao, KM | 1 |
| Lin, TY | 1 |
| Huang, YB | 1 |
| Kuo, CC | 1 |
| Chen, CY | 1 |
| Andersen, S | 1 |
| Schultz, JG | 1 |
| Andersen, A | 1 |
| Ringgaard, S | 1 |
| Nielsen, JM | 1 |
| Holmboe, S | 1 |
| Vildbrad, MD | 1 |
| de Man, FS | 2 |
| Bogaard, HJ | 1 |
| Vonk-Noordegraaf, A | 2 |
| Nielsen-Kudsk, JE | 1 |
| Boivin, V | 1 |
| Beyersdorf, N | 1 |
| Palm, D | 1 |
| Nikolaev, VO | 1 |
| Schlipp, A | 1 |
| Müller, J | 1 |
| Schmidt, D | 1 |
| Kocoski, V | 1 |
| Kerkau, T | 1 |
| Hünig, T | 1 |
| Ertl, G | 1 |
| Lohse, MJ | 1 |
| Jahns, R | 1 |
| Kubota, Y | 1 |
| Asai, K | 1 |
| Furuse, E | 1 |
| Murai, K | 1 |
| Tsukada, YT | 1 |
| Shimizu, W | 1 |
| Remme, WJ | 2 |
| Handoko, ML | 1 |
| van Ballegoij, JJ | 1 |
| Schalij, I | 1 |
| Bogaards, SJ | 1 |
| Postmus, PE | 1 |
| van der Velden, J | 1 |
| Westerhof, N | 1 |
| Paulus, WJ | 1 |
| Sarraf, M | 1 |
| Francis, GS | 1 |
| Furrer, F | 1 |
| Giambarba, C | 1 |
| Strauer, BE | 1 |
| Schwartzkopff, B | 1 |
| Czuriga, I | 1 |
| Edes, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Preventing Adverse Cardiac Events in Chronic Obstructive Pulmonary Disease[NCT03917914] | Phase 3 | 280 participants (Actual) | Interventional | 2020-06-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for bisoprolol and Disease Exacerbation
| Article | Year |
|---|---|
Do beta-adrenergic blocking agents increase asthma exacerbation? A network meta-analysis of randomized controlled trials.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Atenolol; Bisoprolol; Cardiovascular Diseases; Ce | 2021 |
β-blockers in stage B: a precursor of heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Benzazepines; Bisoprolol; Carbazoles; Cardiovascular System; C | 2012 |
Beta blockers or angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker: what should be first?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Carbazoles; Carve | 2007 |
[Role of beta-blockers in the treatment of chronic heart heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Controlled Clinica | 2001 |
2 trials available for bisoprolol and Disease Exacerbation
| Article | Year |
|---|---|
Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS).
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Adult; Anti-Bacterial Agents; Bisoprolol; Dise | 2022 |
Preventing adverse cardiac events (PACE) in chronic obstructive pulmonary disease (COPD): study protocol for a double-blind, placebo controlled, randomised controlled trial of bisoprolol in COPD.
Topics: Bisoprolol; Disease Progression; Double-Blind Method; Forced Expiratory Volume; Humans; Pulmonary Di | 2021 |
10 other studies available for bisoprolol and Disease Exacerbation
| Article | Year |
|---|---|
Beta-blocker Use in Moderate and Severe Chronic Obstructive Pulmonary Disease.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bisoprolol; Case-Control | 2019 |
An attempt at administering a transdermal formulation of bisoprolol in patients with acute cardiac symptoms.
Topics: Acute Coronary Syndrome; Acute Disease; Administration, Cutaneous; Adrenergic beta-1 Receptor Antago | 2021 |
The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chi-Square | 2017 |
Effects of bisoprolol and losartan treatment in the hypertrophic and failing right heart.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Bisoprolol | 2014 |
Novel receptor-derived cyclopeptides to treat heart failure caused by anti-β1-adrenoceptor antibodies in a human-analogous rat model.
Topics: Animals; Antibodies; B-Lymphocytes; Bisoprolol; CD4-Positive T-Lymphocytes; Disease Models, Animal; | 2015 |
Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol | 2015 |
Which beta-blocker is most effective in heart failure?
Topics: Adrenergic beta-Antagonists; Animals; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Clinical Tria | 2010 |
Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Antihypertensive Agents; Bisoprolol; Disease Models | 2012 |
[The choked heart].
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Bisoprolol; Calcium Channel Blockers; Cardia | 2012 |
Objectives of high blood pressure treatment: left ventricular hypertrophy, diastolic function, and coronary reserve.
Topics: Antihypertensive Agents; Arterioles; Bisoprolol; Blood Pressure; Coronary Circulation; Diastole; Dil | 1998 |